Wanqiong Li

1.1k total citations · 1 hit paper
29 papers, 830 citations indexed

About

Wanqiong Li is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Wanqiong Li has authored 29 papers receiving a total of 830 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Immunology, 14 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Wanqiong Li's work include Immunotherapy and Immune Responses (14 papers), Immune Cell Function and Interaction (9 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Wanqiong Li is often cited by papers focused on Immunotherapy and Immune Responses (14 papers), Immune Cell Function and Interaction (9 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Wanqiong Li collaborates with scholars based in China and Hong Kong. Wanqiong Li's co-authors include Yanfeng Gao, Guanyu Chen, Xiuman Zhou, Yuanming Qi, Wenjie Zhai, Shaomeng Chen, Yahong Wu, Jiangfeng Du, Xinghua Sui and Wenshan Zhao and has published in prestigious journals such as Angewandte Chemie International Edition, Nature Communications and Nano Letters.

In The Last Decade

Wanqiong Li

24 papers receiving 816 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy

2025 27 citations Wanqiong Li, Xin Yang et al. Nature Communications profile →

Peers

Countries citing papers authored by Wanqiong Li

Since Specialization

Citations

This map shows the geographic impact of Wanqiong Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wanqiong Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wanqiong Li more than expected).

Fields of papers citing papers by Wanqiong Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wanqiong Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wanqiong Li. The network helps show where Wanqiong Li may publish in the future.

Co-authorship network of co-authors of Wanqiong Li

This figure shows the co-authorship network connecting the top 25 collaborators of Wanqiong Li. A scholar is included among the top collaborators of Wanqiong Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wanqiong Li. Wanqiong Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development of a Cascade-Targeting Oral Vaccine via Glycoprotein 2 on Intestinal Microfold Cells for Cancer Immunotherapy 2025 ·Nano Letters ·Wanqiong Li, Xin Yang, Mengfan Wang, Zheng Hu, Shaomeng Chen, Xinghua Sui, (unknown), (unknown), (unknown), (unknown), Xiuman Zhou, Guanyu Chen, Yanfeng Gao	2
2	VISTA as a context-dependent immune checkpoint: Implications for tumor immunity and autoimmune pathogenesis 2025 ·Biochimica et Biophysica Acta (BBA) - Reviews on Cancer ·(unknown), Beibei Li, Feng Luo, Wanqiong Li, Xiuman Zhou, (unknown)	0
3	A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy breakdown → 2025 ·Nature Communications ·(unknown), (unknown), Wanqiong Li, (unknown), (unknown), Xin Yang, (unknown), Mengfan Wang, (unknown), Ye Su, Feng Luo, Guanyu Chen, Juan Liu, Xinghua Sui, Xiuman Zhou, Yanfeng Gao	27
4	An oral vaccine based on stable peptide-chitosan conjugate targeting DEC-205 for cancer immunotherapy 2025 ·Journal of Controlled Release ·Mengfan Wang, Xiaoyun Ye, Wanqiong Li, (unknown), Xin Zhao, (unknown), Xinghua Sui, (unknown), Feng Luo, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Ye Su, (unknown), (unknown), Yanfeng Gao	0
5	Adult-onset hypothyroidism induces granulosa cell apoptosis and affects ovarian follicle development in rats 2025 ·Frontiers in Cell and Developmental Biology ·Shuyue Li, (unknown), Wanqiong Li, (unknown), (unknown), Xi Xiao, Zhigang Xue, Jinfeng Xue, Yazhong Ji	0
6	Double emission CDs modified with rhodamine B for ratiometric sensing detection and bioimaging 2023 ·Diamond and Related Materials ·(unknown), Yan Zhang, Zheng Fu, (unknown), Liuping Zhang, Wanqiong Li, (unknown), Fengling Cui	4
7	Fish oil-based microemulsion can efficiently deliver oral peptide blocking PD-1/PD-L1 and simultaneously induce ferroptosis for cancer immunotherapy 2023 ·Journal of Controlled Release ·Xin Yang, Wanqiong Li, Shuzhen Li, Shaomeng Chen, Zheng Hu, (unknown), Xueqin Zhu, (unknown), Xiuman Zhou, (unknown), (unknown), Juan Liu, Xinghua Sui, Guanyu Chen, Yanfeng Gao	24
8	Development of a novel peptide targeting GPR81 to suppress adipocyte-mediated tumor progression 2023 ·Biochemical Pharmacology ·Shaomeng Chen, Xiuman Zhou, Wanqiong Li, Xin Yang, (unknown), Zheng Hu, Shuzhen Li, Guan‐Yu Chen, Xinghua Sui, Juan Liu, Yanfeng Gao	6
9	Immune and oxidative stress disorder in ovulation-dysfunction women revealed by single-cell transcriptome 2023 ·Frontiers in Immunology ·(unknown), Yumei Li, (unknown), (unknown), Xunyi Zhang, Wanqiong Li, (unknown), Xian Chen, Yazhong Ji, Zhigang Xue, Bo Lv	18
10	Design of a novel chimeric peptide via dual blockade of CD47/SIRPα and PD-1/PD-L1 for cancer immunotherapy 2023 ·Science China Life Sciences ·Zheng Hu, Wanqiong Li, Shaomeng Chen, (unknown), Ran Xu, (unknown), Xin Yang, Shuzhen Li, Xiuman Zhou, (unknown), (unknown), (unknown), (unknown), Juan Liu, Xinghua Sui, Yanfeng Gao	22
11	Dual Blockade of Lactate/GPR81 and PD-1/PD-L1 Pathways Enhances the Anti-Tumor Effects of Metformin 2021 ·Biomolecules ·Shaomeng Chen, Xiuman Zhou, (unknown), Wanqiong Li, Shuzhen Li, Zheng Hu, Ling Chen, (unknown), Juan Liu, Guanyu Chen, (unknown), Xianxing Jiang, Xinghua Sui, Yanfeng Gao	39
12	An orally available PD-1/PD-L1 blocking peptide OPBP-1-loaded trimethyl chitosan hydrogel for cancer immunotherapy 2021 ·Journal of Controlled Release ·Wanqiong Li, Xueqin Zhu, Xiuman Zhou, Xiaoxi Wang, Wenjie Zhai, Bingyu Li, Jiangfeng Du, Guodong Li, Xinghua Sui, Yahong Wu, (unknown), Yuanming Qi, Guanyu Chen, Yanfeng Gao	73
13	Computer-aided design of PVR mutants with enhanced binding affinity to TIGIT 2021 ·Cell Communication and Signaling ·Xiaowen Zhou, Jiangfeng Du, Xiuman Zhou, (unknown), Wanqiong Li, Chunxia Chen, (unknown), (unknown), Shanshan Gou, Yixuan Sun, Wenjie Zhai, Lu Qiu, Yuanming Qi, Wenshan Zhao, Yanfeng Gao	6
14	A Novel d‐Peptide Identified by Mirror‐Image Phage Display Blocks TIGIT/PVR for Cancer Immunotherapy 2020 ·Angewandte Chemie International Edition ·Xiuman Zhou, Chao Zuo, Wanqiong Li, Weiwei Shi, Xiaowen Zhou, Hongfei Wang, Shaomeng Chen, Jiangfeng Du, Guanyu Chen, Wenjie Zhai, Wenshan Zhao, Yahong Wu, Yuanming Qi, Lei Liu, Yanfeng Gao	121
15	A Novel d‐Peptide Identified by Mirror‐Image Phage Display Blocks TIGIT/PVR for Cancer Immunotherapy 2020 ·Angewandte Chemie ·Xiuman Zhou, Chao Zuo, Wanqiong Li, Weiwei Shi, Xiaowen Zhou, Hongfei Wang, Shaomeng Chen, Jiangfeng Du, Guanyu Chen, Wenjie Zhai, Wenshan Zhao, Yahong Wu, Yuanming Qi, Lei Liu, Yanfeng Gao	2
16	CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy 2020 ·Journal for ImmunoTherapy of Cancer ·Hongfei Wang, Yixuan Sun, Xiuman Zhou, Chunxia Chen, (unknown), Wanqiong Li, Shanshan Gou, Yanying Li, Jiangfeng Du, Guanyu Chen, Wenjie Zhai, Yahong Wu, Yuanming Qi, Yanfeng Gao	101
17	Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy 2020 ·Science China Life Sciences ·Wenjie Zhai, Xiuman Zhou, (unknown), Wanqiong Li, (unknown), Yixuan Sun, Jiangfeng Du, Wenshan Zhao, Lei Xing, Yuanming Qi, Yanfeng Gao	41
18	Single-Cell Transcriptomic Analysis Reveals Mitochondrial Dynamics in Oocytes of Patients With Polycystic Ovary Syndrome 2020 ·Frontiers in Genetics ·(unknown), Boxuan Liu, Xian Chen, Qiwei Liu, Wanqiong Li, Bo Lv, Xiaoyu Xu, Lu Wang, Qiao Zeng, Jinfeng Xue, Zhigang Xue	44
19	A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses 2020 ·Acta Pharmaceutica Sinica B ·Wenjie Zhai, Xiuman Zhou, (unknown), Wanqiong Li, Guanyu Chen, Xinghua Sui, Guodong Li, Yuanming Qi, Yanfeng Gao	71
20	Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells 2018 ·Frontiers in Immunology ·Xiuman Zhou, Wanqiong Li, Yahong Wu, Lu Han, Xinguang Cao, Xuanming Yang, (unknown), Wenshan Zhao, Wenjie Zhai, Yuanming Qi, Yanfeng Gao	84

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact